

ONKOLOJİK TEDAVİLERİN FETÜSE ETKİLERİ

5. BÖLÜM

Sebahattin ÇELİK¹
Selim GÜLÜCÜ²

GİRİŞ

Term gebeliklerin yaklaşık 1/1000'i kanser ile komplikedir⁽¹⁾. Gebelikte güvenle kullanılacak tanı yöntemlerinin olması ve gebeği yaşamın geç dönemlerine erteleme eğilimi ile birliklikte insidansın artması beklenmektedir⁽²⁾. Gebelikte en sık görülen maligniteler; meme kanseri, serviks kanseri, tiroid kanser, hematolojik maligniteler ve melanomdur⁽³⁾. Gebe kanser tedavisi standart bir yaklaşımdan yoksundur. Fetal toksisite korkusu doktorların gebelik sırasında onkolojik tedaviye başlamasını yakın zamana kadar genellikle engelledi. Gebeliğin sonlandırılması, maternal tedavinin geciktirilmesi veya erken doğum yaptırılması gibi durumlar sık sık meydana geldi. Dolayısıyla anne karnında kanser tedavisine maruz kalan çocukların zihinsel ve fiziksel durumlarını gösteren iyi dökümente edilmiş sonuçların varlığı, gebelik döneminde kanser tedavisine yaklaşım konusunda doktorların ve ebeveynlerin en iyi kararı vermelerine fayda sağlayacaktır.

GEBELİKTE KANSER TEDAVİSİ

Teşhis ve evreleme sonrasında fetal güvenliği tehlikeye atmadan, iyi tanımlanmış koşullar altında, devam eden gebelik sırasında onkolojik tedavi mümkündür. Kanser tedavisinde üç ana yöntemi vardır: cerrahi, radyoterapi ve sistematik tedavidir⁽⁴⁾.

Cerrahi

Onkolojik tedavinin önemli bir parçası olan cerrahi pek çok kanser türünde uygulanmaktadır. Belli önlemler alındığında gebelikte cerrahi mümkündür.

¹ Op. Dr., Balıkesir Devlet Hastanesi Kadın Hastalıkları ve Doğum Kliniği, drscelik@yahoo.com

² Dr. Öğr. Üyesi, Gaziosmanpaşa Üniversitesi Kadın Hast. ve Doğum AD, selimgulucu@gop.edu.tr

KAYNAKÇA

1. Pentheroudakis G, Pavlidis N. Cancer and pregnancy: poena magna, not anymore. *European Journal of Cancer* 2006; 42: 126-140.
2. Berkowitz GS, Skovron ML, Lapinski RH ve ark. Delayed childbearing and the outcome of pregnancy. *New England Journal of Medicine* 1990; 322: 659-664.
3. Pereg D, Koren G, Lishner M. Cancer in pregnancy: gaps, challenges and solutions. *Cancer Treatment Reviews* 2008; 34: 302-312.
4. Tineke Vandenbroucke, Magali Verheecke, Monica Fumagalli, Christianne Lok, Frédéric Amant. Effects of cancer treatment during pregnancy on fetal and child development. *The Lancet Child & Adolescent Health* 2017;4(1):302-310
5. Allaert SE, Carlier SP, Weyne LP, Vertommen DJ, Dutre PE, Desmet MB. First trimester anesthesia exposure and fetal outcome. A review. *Acta Anaesthesiol Belg.* 2007;58(2):119-23.
6. Mazze RI, Kallen B. Reproductive outcome after anesthesia and operation during pregnancy: a registry study of 5405 cases. *Am J Obstet Gynecol.* 1989;161(5):1178-85.
7. Cohen-Kerem R, Railton C, Oren D, Lishner M, Koren G. Pregnancy outcome following non-obstetric surgical intervention. *Am J Surg.* 2005;190(3):467-73.
8. Moran BJ, Yano H, Al Zahir N, Farquharson M. Conflicting priorities in surgical intervention for cancer in pregnancy. *Lancet Oncol.* 2007;8(6):536-44.
9. Evans SR, Sarani B, Bhanot P, Feldman E. Surgery in pregnancy. *Curr Probl Surg.* 2012;49(6):333-88.
10. Pearl J, Price R, Richardson W, Fanelli R, Society of American Gastrointestinal Endoscopic S. Guidelines for diagnosis, treatment, and use of laparoscopy for surgical problems during pregnancy. *Surg Endosc.* 2011;25(11):3479-92.
11. Amant F, Van Calsteren K, Halaska MJ, Beijnen J, Lagae L, Hanssens M, et al. Gynecologic cancers in pregnancy: guidelines of an international consensus meeting. *Int J Gynecol Cancer.* 2009;19 Suppl 1:S1-12.
12. Kal HB, Struikmans H. Radiotherapy during pregnancy: fact and fiction. *Lancet Oncol.* 2005;6(5):328-33.
13. ICRP. Biological Effects after Prenatal Irradiation (Embryo and Fetus). ICRP Publication 90. *Ann ICRP.* 2003;33(1-2).
14. Otake M, Schull WJ. In utero exposure to A-bomb radiation and mental retardation; a reassessment. *Br J Radiol.* 1984;57(677):409-14.
15. Mazonakis M, Varveris H, Damilakis J, Theoharopoulos N, Gourtsoyiannis N. Radiation dose to conceptus resulting from tangential breast irradiation. *Int J Radiat Oncol Biol Phys.* 2003;55(2):386-91.
16. Van Calsteren K, Verbesselt R, Beijnen J, Devlieger R, De Catte L, Chai DC, et al. Transplacental transfer of anthracyclines, vinblastine, and 4-hydroxy-cyclophosphamide in a baboon model. *Gynecol Oncol.* 2010;119(3):594-600.
17. Van Calsteren K, Verbesselt R, Devlieger R, De Catte L, Chai DC, Van Bree R, et al. Transplacental transfer of paclitaxel, docetaxel, carboplatin, and trastuzumab in a baboon model. *Int J Gynecol Cancer.* 2010;20(9):1456-64.
18. Amant F, Vandenbroucke T, Verheecke M, Fumagalli M, Halaska MJ, Boere I, et al. Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy. *New Engl J Med.* 2015;373(19):1824-34.
19. Van Calsteren K, Heyns L, De Smet F, Van Eycken L, Gziri MM, Van Gemert W, et al. Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. *J Clin Oncol.* 2010;28(4):683-9.
20. Amant F, Van Calsteren K, Halaska MJ, Gziri MM, Hui W, Lagae L, et al. Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. *Lancet Oncol.* 2012;13(3):256-64.

21. Murthy RK, Theriault RL, Barnett CM, Hodge S, Ramirez MM, Milbourne A, et al. Outcomes of children exposed in utero to chemotherapy for breast cancer. *Breast Cancer Res.* 2014;16(6):500.
22. Cardonick EH, Gringlas MB, Hunter K, Greenspan J. Development of children born to mothers with cancer during pregnancy: comparing in utero chemotherapy-exposed children with nonexposed controls. *Am J Obstet Gynecol.* 2015;212(5).
23. Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. *Lancet Oncology.* 2004;5(5):283-91.
24. Mendelsohn J. Personalizing oncology: perspectives and prospects. *J Clin Oncol.* 2013;31(15):1904-11.
25. Lambertini M, Peccatori FA, Azim HA, Jr. Targeted agents for cancer treatment during pregnancy. *Cancer Treat Rev.* 2015;41(4):301-9.
26. Zagouri F, Sergeantanis TN, Chrysikos D, Papadimitriou CA, Dimopoulos MA, Bartsch R. Trastuzumab administration during pregnancy: a systematic review and meta-analysis. *Breast Cancer Res Treat.* 2013;137(2):349-57.
27. Tewari K, Bonebrake RG, Asrat T, Shanberg AM. Ambiguous genitalia in infant exposed to tamoxifen in utero. *Lancet.* 1997;350(9072):183.
28. Berger JC, Clericuzio CL. Pierre Robin sequence associated with first trimester fetal tamoxifen exposure. *Am J Med Genet A.* 2008;146A(16):2141-4.
29. Cullins SL, Pridjian G, Sutherland CM. Goldenhar's syndrome associated with tamoxifen given to the mother during gestation. *JAMA.* 1994;271(24):1905-6.
30. Barthelmes L, Gateley CA. Tamoxifen and pregnancy. *Breast.* 2004;13(6):446-51.
31. Drew JH, Parkinson P, Walstab JE, Beischer NA. Incidences and types of malformations in newborn infants. *Med J Aust.* 1977;1(26):945-9.
32. Nicholson HO. Cytotoxic drugs in pregnancy. Review of reported cases. *J Obstet Gynaecol Br Commonw.* 1968;75(3):307-12.
33. Ebert U, Löffler H, Kirch W. Cytotoxic therapy and pregnancy. *Pharmacol Ther.* 1997;74(2):207-20.
34. Doll DC, Ringenberg QS, Yarbrow JW. Management of cancer during pregnancy. *Arch Intern Med.* 1988;148(9):2058-64.
35. Aviles A, Neri N, Nambo MJ. Hematological malignancies and pregnancy: treat or not treat during first trimester. *Int J Cancer.* 2012;131(11):2678-83.
36. Han SN, Gziri MM, Van Calsteren K, Amant F. Is chemotherapy during the first trimester of pregnancy really safe? *Int J Cancer.* 2013;132(7):1728.
37. Aviles A, Neri N. Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero. *Clin Lymphoma.* 2001;2(3):173-7.
38. Loibl S, Han SN, von Minckwitz G, Bontenbal M, Ring A, Giermek J, et al. Treatment of breast cancer during pregnancy: an observational study. *Lancet Oncol.* 2012;13(9):887-96.
39. Abdel-Hady e-S, Hemida RA, Gamal A, El-Zafarany M, Toson E, El-Bayoumi MA. Cancer during pregnancy: perinatal outcome after in utero exposure to chemotherapy. *Arch Gynecol Obstet.* 2012;286(2):283-6.
40. Pallotto EK, Kilbride HW. Perinatal outcome and later implications of intrauterine growth restriction. *Clin Obstet Gynecol.* 2006;49(2):257-69.
41. Sankaran S, Kyle PM. Aetiology and pathogenesis of IUGR. *Best Pract Res Clin Obstet Gynaecol.* 2009;23(6):765-77.
42. Wadhwa PD, Garite TJ, Porto M, Glynn L, Chicz-DeMet A, Dunkel-Schetter C, et al. Placental corticotropin-releasing hormone (CRH), spontaneous preterm birth, and fetal growth restriction: a prospective investigation. *Am J Obstet Gynecol.* 2004;191(4):1063-9.
43. Maulik D, Frances Evans J, Ragolia L. Fetal growth restriction: pathogenic mechanisms. *Clin Obstet Gynecol.* 2006;49(2):219-27.
44. Lu D, Ludvigsson JF, Smedby KE, Fall K, Valdimarsdottir U, Cnattingius S, et al. Maternal Cancer During Pregnancy and Risks of Stillbirth and Infant Mortality. *J Clin Oncol.* 2017;35(14):1522-9.

45. Cardonick E, Usmani A, Ghaffar S. Perinatal Outcomes of a Pregnancy Complicated by Cancer, Including Neonatal Follow-Up After in Utero Exposure to Chemotherapy Results of an International Registry. *Am J Clin Oncol-Canc.* 2010;33(3):221-8.
46. Wang ML, Dorer DJ, Fleming MP, Catlin EA. Clinical outcomes of near-term infants. *Pediatrics.* 2004;114(2):372-6.
47. Cardonick E, Gilmandyar D, Somer RA. Maternal and Neonatal Outcomes of Dose-Dense Chemotherapy for Breast Cancer in Pregnancy. *Obstet Gynecol.* 2012;120(6):1267-72.
48. Chang A, Patel S. Treatment of acute myeloid leukemia during pregnancy. *Ann Pharmacother.* 2015;49(1):48-68.
49. Broder H, Gottlieb RA, Lepor NE. Chemotherapy and cardiotoxicity. *Rev Cardiovasc Med.* 2008;9(2):75-83.
50. Mertens AC, Yasui Y, Neglia JP, Potter JD, Nesbit ME, Ruccione K, et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. *J Clin Oncol.* 2001;19(13):3163-72.
51. Zucchi R, Danesi R. Cardiac toxicity of antineoplastic anthracyclines. *Curr Med Chem Anti-cancer Agents.* 2003;3(2):151-71.
52. Aviles A, Neri N, Nambo MJ. Long-term evaluation of cardiac function in children who received anthracyclines during pregnancy. *Ann Oncol.* 2006;17(2):286-8.
53. Gziri MM, Amant F, Debieve F, Van Calsteren K, De Catte L, Mertens L. Effects of chemotherapy during pregnancy on the maternal and fetal heart. *Prenat Diagn.* 2012;32(7):614-9.
54. Clemens E, de Vries AC, Pluijm SF, Am Zehnhoff-Dinnesen A, Tissing WJ, Loonen JJ, et al. Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study. *Eur J Cancer.* 2016;69:77-85.
55. Caballero M, Mackers P, Reig O, Buxo E, Navarrete P, Blanch JL, et al. The Role of Audiometry prior to High-Dose Cisplatin in Patients with Head and Neck Cancer. *Oncology.* 2017.
56. Geijteman EC, Wensveen CW, Duvekot JJ, van Zuylen L. A child with severe hearing loss associated with maternal cisplatin treatment during pregnancy. *Obstet Gynecol.* 2014;124(2 Pt 2 Suppl 1):454-6.
57. Dens F, Boute P, Otten J, Vinckier F, Declerck D. Dental caries, gingival health, and oral hygiene of long term survivors of paediatric malignant diseases. *Arch Dis Child.* 1995;72(2):129-32.
58. Peretz B, Peretz T. The effect of chemotherapy in pregnant women on the teeth of offspring. *Pediatr Dent.* 2003;25(6):601-4.
59. Mennes M, Stiers P, Vandebussche E, Vercruyse G, Uyttebroeck A, De Meyer G, et al. Attention and information processing in survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only. *Pediatr Blood Cancer.* 2005;44(5):478-86.
60. Lofstad GE, Reinfjell T, Hestad K, Diseth TH. Cognitive outcome in children and adolescents treated for acute lymphoblastic leukaemia with chemotherapy only. *Acta Paediatr.* 2009;98(1):180-6.
61. Jackson GE. Chemo brain - a psychotropic drug phenomenon? *Med Hypotheses.* 2008;70(3):572-7.
62. Van den Bergh BRH, Mulder EJH, Mennes M, Glover V. Antenatal maternal anxiety and stress and the neurobehavioural development of the fetus and child: links and possible mechanisms. A review. *Neurosci Biobehav R.* 2005;29(2):237-58.